Arlov, Sweden

Eva Maria Dahlen

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Arlov, SE (2017 - 2020)
  • Lund, SE (2017 - 2023)

Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Journey of Eva Maria Dahlen: A Trailblazer in Bispecific Polypeptides

Introduction: Eva Maria Dahlen, an accomplished inventor based in Arlov, Sweden, has made significant contributions to the field of biotechnology through her innovative work on bispecific polypeptides. With six patents to her name, Eva's research focuses on developing therapeutics that target multiple T cell receptors, enhancing the potential for cancer treatment and immunotherapy.

Latest Patents: One of Eva's latest inventions involves bispecific polypeptides that comprise two distinct binding domains. These domains are designed to bind specifically to different T cell targets, facilitating a targeted immune response. The first binding domain can attach to a variety of T cell targets, including OX40, CTLA-4, CD137, CD27, GITR, and CD28. This groundbreaking technology aims to improve the efficacy of cancer therapies by harnessing the power of the immune system.

Career Highlights: Eva Maria Dahlen is currently affiliated with Alligator Bioscience AB, a company at the forefront of developing innovative cancer immunotherapies. Throughout her career, she has focused on leveraging her expertise in biotechnology and immunology to create advanced therapeutic options for patients with cancer. Her dedication to research and innovation has positioned her as a key figure in her field.

Collaborations: In her work at Alligator Bioscience AB, Eva collaborates closely with her esteemed colleagues, including Peter Ellmark and Christina Furebring. Together, they share a commitment to advancing the understanding of immunology and developing novel therapies that can address the complexities of cancer treatment.

Conclusion: Eva Maria Dahlen's contributions to the field of biotechnology through her patents on bispecific polypeptides highlight her role as an influential inventor. As she continues to advance cancer therapies, her work not only paves the way for innovative treatments but also exemplifies the impact of dedicated scientists in the ongoing battle against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…